117 related articles for article (PubMed ID: 9641228)
1. Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer.
Topuz E; Saip P; Aydmer A; Salihoğlu Y; Berkman S; Bengisu E
Eur J Gynaecol Oncol; 1998; 19(3):265-70. PubMed ID: 9641228
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.
Topuz E; Eralp Y; Saip P; Aydiner A; Taş F; Saliho Y; Salihoğlu Y; Berkman S; Bengisu E
Eur J Gynaecol Oncol; 2001; 22(1):70-3. PubMed ID: 11321501
[TBL] [Abstract][Full Text] [Related]
3. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
Dufour P; Bergerat JP; Barats JC; Giron C; Duclos B; Dellenbach P; Ritter J; Renaud R; Audhuy B; Oberling F
Cancer; 1994 Apr; 73(7):1865-9. PubMed ID: 8137212
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal cisplatin--mitoxantrone in ovarian cancer patients with minimal residual disease.
Topuz E; Aydiner A; Saip P; Bengisu E; Berkman S; Disci R
Eur J Gynaecol Oncol; 1997; 18(1):71-5. PubMed ID: 9061330
[TBL] [Abstract][Full Text] [Related]
6. A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer.
Nardi M; Della Giulia M; Pollera CF; Marolla P; Ruggeri EM; Iacovelli A; Atlante G; Calabresi F
Cancer Chemother Pharmacol; 1996; 38(3):298-301. PubMed ID: 8646807
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease.
Frasci G; Tortoriello A; Facchini G; Conforti S; Cardone A; Persico G; Mastrantonio P; Iaffaioli RV
Gynecol Oncol; 1993 Jul; 50(1):60-7. PubMed ID: 8349166
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Gynecol Oncol; 1999 Apr; 73(1):96-101. PubMed ID: 10094887
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
[TBL] [Abstract][Full Text] [Related]
13. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal chemotherapy with cisplatin and etoposide in ovarian carcinoma patients who are clinically in complete remission.
Menczer J; Ben-Baruch G; Rizel S; Brenner H
Eur J Gynaecol Oncol; 1995; 16(1):12-7. PubMed ID: 7744111
[TBL] [Abstract][Full Text] [Related]
15. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
[TBL] [Abstract][Full Text] [Related]
17. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1990 Jul; 8(7):1226-30. PubMed ID: 2113570
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
Vallejos C; Solidoro A; Gómez H; Castellano C; Barriga O; Galdos R; Casanova L; Otero J; Rodriguez W
Gynecol Oncol; 1997 Nov; 67(2):168-71. PubMed ID: 9367702
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
20. Positive experience of intraperitoneal chemotherapy followed by intravenous chemotherapy in heavily pretreated patients with suboptimal residual ovarian cancer and primary peritoneal cancer.
Nicoletto MO; Dalla Palma M; Donach ME; Gusella M; Cappetta A; Shams M; Marchet A; Nardin M; Pintacuda G; Di Maggio A; Marchesi M; Carli P; Fiduccia P; Artioli G; Nitti D
Tumori; 2010; 96(6):918-25. PubMed ID: 21388052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
